Surmodics Inc (OQ:SRDX)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 9924 W 74th St EDEN PRAIRIE MN 55344 |
| Tel: | N/A |
| Website: | https://www.surmodics.com |
| IR: | See website |
| Key People | ||
| Gary R. Maharaj President, Chief Executive Officer, Director | Timothy J. Arens Chief Financial Officer, Senior Vice President - Finance and Information Technology | Gordon S. Weber Senior Vice President - Legal, General Counsel, Secretary |
| Joseph J. Stich Senior Vice President of Human Resources, President - In Vitro Diagnostics | Charles W. Olson Senior Vice President, President - Medical Device Coatings | Teri L.W. Sides Senior Vice President, President - Vascular Interventions |
| Business Overview |
| Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. |
| Financial Overview |
| For the three months ended 31 December 2023, Surmodics Inc revenues increased 23% to $30.6M. Net loss decreased 90% to $786K. Revenues reflect Medical Device segment increase of 24% to $23.5M, In Vitro Diagnostics segment increase of 18% to $7M. Lower net loss reflects Medical Device segment loss decrease of 97% to $224K, In Vitro Diagnostics segment income increase of 6% to $3.1M. |
| Employees: | 376 as of Sep 30, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $377.50M as of Dec 31, 2023 |
| Annual revenue (TTM): | $138.20M as of Dec 31, 2023 |
| EBITDA (TTM): | $22.07M as of Dec 31, 2023 |
| Net annual income (TTM): | $5.52M as of Dec 31, 2023 |
| Free cash flow (TTM): | $9.86M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 14,236,000 as of Jan 29, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.